Ondine Biomedical (LSE:OBI) ROCE % : -1,333.03% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ondine Biomedical's annualized ROCE % for the quarter that ended in Jun. 2024 was -1,333.03%.

Ondine Biomedical ROCE % Historical Data

The historical data trend for Ondine Biomedical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical ROCE % Chart

Ondine Biomedical Annual Data

Trend

Dec08

Dec09

Dec10

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-92.02

-188.65

Ondine Biomedical Semi-Annual Data
	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-67.48	-118.02	-179.16	-368.05	-1,333.03

Ondine Biomedical ROCE % Calculation

Ondine Biomedical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.464	/	( ( (10.013 - 2.361)	+	(3.376 - 2.055) )	/ 2 )
	=	-8.464	/	( (7.652	+	1.321)	/ 2 )
	=	-8.464	/	4.4865
	=	-188.65 %

Ondine Biomedical's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-8.878	/	( ( (3.376 - 2.055)	+	(2.308 - 2.297) )	/ 2 )
	=	-8.878	/	( ( 1.321	+	0.011 )	/ 2 )
	=	-8.878	/	0.666
	=	-1,333.03 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Ondine Biomedical (LSE:OBI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ondine Biomedical ROCE % Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ondine Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OBIMF:USA VF5:Germany

Address

1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6

Website

https://www.ondinebio.com

Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical Headlines

No Headlines